Christopher Moxham
Chief Executive Officer at Rarebase, PBC
Profile
Dr. Christopher Moxham is a Chief Executive & Scientific Officer at Transcripta Bio, Inc. and a President & Chief Executive Officer at Rarebase, PBC.
Dr. Moxham was previously employed as a Chief Scientific Officer by Fulcrum Therapeutics, Inc. and a Head-Drug Discovery by Eli Lilly & Co.
He received his undergraduate degree from Cornell University and a doctorate degree from Stony Brook University.
Christopher Moxham active positions
| Companies | Position | Start |
|---|---|---|
Rarebase, PBC
 Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Chief Executive Officer | 04/10/2023 |
Former positions of Christopher Moxham
| Companies | Position | End |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| FULCRUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Christopher Moxham
| Cornell University | Undergraduate Degree |
| Stony Brook University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
- Stock Market
- Insiders
- Christopher Moxham
